Comparative Pharmacology
Head-to-head clinical analysis: INCRELEX versus IPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCRELEX versus IPLEX.
INCRELEX vs IPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; clinically, steady-state is achieved within 2-3 days.
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Renal: ~95% of absorbed dose as unchanged drug and metabolites; fecal: <5%.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Category C
Category C
Growth Factor
Growth Factor